Saturday, June 19, 2021 7:27:09 PM
The OS for the current standard of care (SOC) to treat ndGBM is currently only 14 to 16 months. They say that DCVax-L will not be approved to treat those subsets of trial patients who had OS increases to 18, 24, 30, 36, 42, 48, and 54 months, compared to the current OS for SOC to treat ndGBM, which is currently only 14 to 16 months.
But, these people fail to realize that the current SOC (the Stupp Protocol) to treat ndGBM, became SOC in 2005, even though it only added about 2 months of OS. Also, the Stupp protocol does not benefit all subsets of ndGBM the same. It benefitted ndGBM differently based on their age, methylation status, gene subtype, etc. But the Stupp protocol was approved by the FDA and regulatory authorities around the world, and it quickly was adopted as SOC to treat ndGBM.
I believe that DCVax-L will be approved for all ndGBM and rGBM patients worldwide, and it will quickly become the new SOC to treat all GBM patients worldwide, regardless of age, gene subtype, methylation status, etc.
Dr. Richard Pazdur says the following around the 32:00 minute mark, regarding the reasons why the FDA started Project Orbis:
https://collaboration.fda.gov/pbq6126oijaa/
Also, note what Dr. Liau says around the 36:00 minute mark in this video:
Here is what Dr. Ashkan Keyoumars said on this video around the 5:30 minute mark, which was released after the 2018 blinded and blended DCVax-L trial data was released:
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM